Knight Therapeutics Inc. (FRA:04K)
Germany · Delayed Price · Currency is EUR | Market Cap | 592.93M +47.0% |
| Revenue (ttm) | 337.34M +42.3% |
| Net Income | 9.17M +3,782.8% |
| EPS | 0.09 +8,835.1% |
| Shares Out | n/a |
| PE Ratio | 64.69 |
| Forward PE | 96.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.00 |
| Previous Close | 5.95 |
| Day's Range | 6.00 - 6.00 |
| 52-Week Range | 3.46 - 6.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Knight Therapeutics
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ... [Read more]
News
Knight Therapeutics Announces Launch of WYNZORA® in Canada
MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueo...
Knight Therapeutics Q2 Earnings Call Highlights
Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and f...
Knight Therapeutics price target raised to C$11 from C$9.50 at Stifel
Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$11 from C$9.50 and keeps a Buy rating on the shares.
Knight Therapeutics price target raised to C$11 from C$9.50 at RBC Capital
RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$11 from C$9.50 and keeps an Outperform rating on the shares.
Knight Therapeutics Earnings Call Transcript: Q2 2026
Record H1 2026 results with CAD 293M revenue and strong EBITDA growth driven by 17 launches. Guidance raised for 2026, expecting at least 20% revenue growth and 15% EBITDA margin, with continued portfolio expansion and stable cash flows supporting future growth.
Knight Therapeutics Registration statement: Q2 2026
Knight Therapeutics filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Knight Therapeutics Registration statement: Q2 2026
Knight Therapeutics filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Knight Therapeutics Earnings release: Q2 2026
Knight Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Notice of Knight Therapeutics’ Second Quarter 2026 Results Conference Call
MONTREAL, July 30, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its second quarter 2026 financial results on Thur...
Knight Therapeutics Announces Repayment of Revolving Credit Facility
MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding un...
Knight to Present at the Jefferies 2026 Healthcare Conference in New York City
MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief ...
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodiu...
Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City
MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) pharmaceutical company, announced today that Samira Sakhia, President and Chief Exec...
Knight Therapeutics price target raised to C$9.50 from C$8.50 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Knight Therapeutics (KHTRF) to C$9.50 from C$8.50 and keeps an Outperform rating on the shares.
Knight Therapeutics resumed with a Buy at Canaccord
Canaccord resumed coverage of Knight Therapeutics (KHTRF) with a Buy rating and C$9.50 price target after the company reported “a very strong set” of Q1 results. The company also took…
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical ...
Knight Therapeutics Earnings Call Transcript: Q1 2026
Record Q1 2026 revenues and adjusted EBITDA were driven by portfolio expansion, strong promoted product growth, and multiple new launches. Fiscal 2026 guidance was raised, supported by robust cash flow, a strengthened balance sheet, and continued focus on acquisitions.
Knight Therapeutics Earnings release: Q1 2026
Knight Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Knight Therapeutics Registration statement: Q1 2026
Knight Therapeutics filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Knight Therapeutics Registration statement: Q1 2026
Knight Therapeutics filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Knight Therapeutics Reports First Quarter 2026 Results
Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from the...
Knight Therapeutics Transcript: AGM 2026
Record revenues and EBITDA were achieved in 2025, driven by acquisitions and product launches. All director nominees and auditors were approved, with a strong focus on growth in Canada and Latin America and disciplined capital allocation.
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on Th...
Knight Therapeutics Slides: Investor presentation
Knight Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.